ClearPoint Neuro Completes Acquisition of IRRAS Holdings, Enhancing CNS Drug Delivery Innovation and Commercial Scale
ClearPoint Neuro Completes Acquisition of IRRAS Holdings, Enhancing CNS Drug Delivery Capabilities
SOLANA BEACH, CALIFORNIA – November 20, 2025 – In a strategic move to bolster its position in the neurocritical care market, ClearPoint Neuro, Inc. (Nasdaq: CLPT) has successfully completed its acquisition of IRRAS Holdings, Inc. The deal, finalized today following shareholder approval, is set to significantly enhance ClearPoint’s operational scale and drive innovation in central nervous system (CNS) drug delivery.
Under the terms of the merger, ClearPoint has invested $5 million in cash and issued 1,325,000 shares of common stock to IRRAS shareholders. Additionally, the agreement includes a revenue-sharing model based on net sales of select IRRAS products, marking a collaborative approach to future growth.
The acquisition brings with it the innovative IRRAflow active fluid-exchange system, a cutting-edge technology aimed at modernizing the management of intracranial bleeding. This addition not only expands ClearPoint’s product offerings but also integrates a robust commercial team and over 50 active customers, enhancing its reach in neurocritical care.
Joe Burnett, President and CEO of ClearPoint Neuro, expressed enthusiasm about the acquisition, stating, “Closing the acquisition of IRRAS is a significant milestone in our strategy to build the leading platform for neuro drug delivery. With IRRAflow now part of our portfolio, we believe we are better positioned to serve patients, hospital systems, and our biopharma partners.”
Will Martin, the former CEO of IRRAS, echoed this sentiment, highlighting the potential for the combined teams to deepen clinical impacts and extend the reach of their technologies. “I believe ClearPoint Neuro is the right organization to take this technology forward,” he said.
ClearPoint Neuro is renowned for its precise navigation systems for the brain and spine, offering both established clinical products and preclinical development services. With this acquisition, the company aims to leverage its enhanced capabilities to drive meaningful value for stakeholders and improve patient outcomes.
As ClearPoint integrates IRRAS into its operations, the company anticipates that the results will be reflected in its consolidated financials starting in the fourth quarter of 2025. This strategic acquisition positions ClearPoint Neuro at the forefront of innovation in CNS therapies, paving the way for future advancements in neurosurgical technologies and biologics.
For more information about ClearPoint Neuro and its offerings, visit www.clearpointneuro.com.
Contact:
Danilo D’Alessandro
Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
SOURCE: ClearPoint Neuro, Inc.
